Oric Pharmaceuticals Files 8-K with Key Agreements and Sales
Ticker: ORIC · Form: 8-K · Filed: May 28, 2025 · CIK: 1796280
| Field | Detail |
|---|---|
| Company | Oric Pharmaceuticals, Inc. (ORIC) |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, regulation-fd
Related Tickers: ORIC
TL;DR
ORIC filed an 8-K on 5/23 covering material agreements, equity sales, and other events.
AI Summary
On May 23, 2025, Oric Pharmaceuticals, Inc. filed an 8-K report detailing several events. These include entering into a material definitive agreement, unregistered sales of equity securities, and other events, alongside financial statements and exhibits. The filing was made on May 28, 2025.
Why It Matters
This 8-K filing indicates significant corporate actions by Oric Pharmaceuticals, potentially impacting its financial structure and operational agreements.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate financial distress or dilution concerns.
Key Players & Entities
- Oric Pharmaceuticals, Inc. (company) — Registrant
- May 23, 2025 (date) — Earliest event reported
- May 28, 2025 (date) — Filing date
- 001-39269 (other) — SEC File Number
- 47-1787157 (other) — IRS Employer Identification No.
FAQ
What specific material definitive agreement did Oric Pharmaceuticals enter into?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities but does not provide details on the type of securities.
What are the 'Other Events' mentioned in the filing?
The filing lists 'Other Events' as a category but does not provide specific details within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 23, 2025.
What is Oric Pharmaceuticals' principal executive office address?
Oric Pharmaceuticals' principal executive office is located at 240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding Oric Pharmaceuticals, Inc. (ORIC).